Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma

British Journal of Cancer

Volumn 113, Issue 9, 2015, Pages 1305-1312

  De Silva, Nadeera ^a   Schulz, Laura ^a   Paterson, Anna ^a   Qain, Wendi ^b   Secrier, Maria ^c   Godfrey, Edmund ^b   Cheow, Heok ^b   O'Donovan, Maria ^b   Lao Sirieix, Pierre ^a   Jobanputra, Minesh ^d   Hochhauser, Daniel ^e   Fitzgerald, Rebecca ^a   Ford, Hugo ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; MET PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; ANASTOMOSIS LEAKAGE; ARTICLE; ATELECTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANDIDIASIS; CHEST INFECTION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; DYSPEPSIA; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; EX VIVO STUDY; FAINTNESS; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GASTRECTOMY; GASTROINTESTINAL PAIN; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SMALL INTESTINE OBSTRUCTION; STOMACH ADENOCARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; WNT SIGNALING PATHWAY; ADENOCARCINOMA; ADJUVANT THERAPY; AGED; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; ESOPHAGEAL NEOPLASMS; GENETICS; LOWER ESOPHAGUS SPHINCTER; MULTICENTER STUDY; PHOSPHORYLATION; PROCEDURES; PROTEOMICS; STOMACH NEOPLASMS;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; NEOADJUVANT THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84946497286     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.342     Document Type: Article

References (39)

1. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27: 5062-5067.
2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
3. CancerResearchUK (2015) Oesophageal cancer incidence statistics Cancer Research UK. Available at: http://www.cancerresearchuk.org/cancer-info/ cancerstats/types/oesophagus/incidence/(accessed on 18 May 2015).
4. Chadwick G, Groene O, Cromwell D, Hardwich R, Riley S, Crosby T, Greenaway K (2013) National Oesophago-Gastric Audit 2013. In: England, T. R. C. O. S. O. (ed.)London.
5. Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR (2012) MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther 11: 660-669.
6. CRUK. Cancer survival rates for patients diagnosed 1996e1999. Survival statistics for the most common cancers. Available at: http://info.cancerresearchuk.org/cancerstats/survival/latestrates/ (accessed 5 February 2009).
7. Cunningham D (2012) A Randomised Phase II/III trial of Perioperative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma. A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas. Protocol Version 6, 28 September 2012.
8. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van De Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20.
9. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46.
10. Cunningham D, Tebbutt NC, Davidenko I, Murad AM, Al-Batran S-E, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe MA, Baker N, Oliner KS, Zhang Y, Hoang T, Sidhu R, Catenacci DVT (2015) Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. ASCO Meet Abstr 33: 4000.
11. Dobbin ZC, Katre AA, Steg AD, Erickson BK, Shah MM, Alvarez RD, ConnerMG, Schneider D, Chen D, Landen CN (2014) Using heterogeneity of the patientderived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget 5: 8750-8764.
12. Duchnowska R, Sperinde J, Chenna A, HaddadM, Paquet A, Lie Y,Weidler JM, Huang W, Winslow J, Jankowski T, Czartoryska-Arlukowicz B,Wysocki PJ, Foszczynska-Kloda M, Radecka B, Litwiniuk MM, Zok J, Wisniewski M, Zuziak D, Biernat W, Jassem J (2014) Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff. Clin Cancer Res 20: 2805-2813.
13. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, Mckenna A, Carter SL, Cibulskis K, Sivachenko A, Saksena G, Voet D, Ramos AH, Auclair D, Thompson K, Sougnez C, Onofrio RC, Guiducci C, Beroukhim R, Zhou Z, Lin L, Lin J, Reddy R, Chang A, Landrenau R, Pennathur A, Ogino S, Luketich JD, Golub TR, Gabriel SB, Lander ES, Beer DG, Godfrey TE, Getz G, Bass AJ (2013) Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45: 478-486.
14. FassanM, Mastracci L, Grillo F, Zagonel V, Bruno S, Battaglia G, Pitto F, Nitti D, Celiento T, Zaninotto G, Fiocca R, Rugge M (2012) Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 61: 769-776.
15. Fischer A, Vazquez-Garcia I, Illingworth CJ, Mustonen V (2014) Highdefinition reconstruction of clonal composition in cancer. Cell Rep 7: 1740-1752.
16. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375: 377-384.
17. Ha SY, Lee J, Jang J, Hong JY, Do IG, Park SH, Park JO, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Park CK, Kang WK, Kim KM (2014) HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy. Int J Cancer 136: 1629-1635.
18. Hecht JR, Bang YJ, Qin S, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero AF, Salman P, Li J, Protsenko S, Buyse ME, Afenjar K, Kaneko T, Kemner A, Santillana S, Press MF, Slamon DJ (2013) Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. J Clin Oncol 31: Abstract LBA4001.
19. Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, Shibata SI, Blanke CD (2011) Southwest Oncology Group study S0413: A phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 22: 2610-2615.
20. Koopman T, Louwen M, Hage M, Smits MM, Imholz AL (2015) Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma. Am J Clin Pathol 143: 257-264.
21. Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, Ley TJ, Mardis ER, Wilson RK, Ding L (2012) SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 28(3): 311-317.
22. Lee J, Kim S, Kim P, Liu X, Lee T, Kim KM, Do IG, Park JO, Park SH, Jang J, Hoe N, Harvie G, Kuller A, Jain A, Meyer G, Leesman G, Park YS, Choi MG, Sohn TS, Bae JM, Lim HY, Singh S, Kang WK (2013a) A novel proteomicsbased clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PLoS One 8: e54644.
23. Lee YY, Kim HP, Kang MJ, Cho BK, Han SW, Kim TY, Yi EC (2013b) Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. Exp Mol Med 45: e64.
24. Li D, Wen X, Ghali L, Al-Shalabi FM, Docherty SM, Purkis P, Iles RK (2008) hCG beta expression by cervical squamous carcinoma-in vivo histological association with tumour invasion and apoptosis. Histopathology 53: 147-155.
25. Liu YJ, Shen D, Yin X, Gavine P, Zhang T, Su X, Zhan P, Xu Y, Lv J, Qian J, Liu C, Sun Y, Qian Z, Zhang J, Gu Y, Ni X (2014) HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br J Cancer 110: 1169-1178.
26. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Hofler H, Fink U, Peschel C, Schwaiger M, Siewert JR (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 8: 797-805.
27. Lorenzen S, Riera Knorrenschild J, Haag GM, Pohl M, Thuss-Patience P, Bassermann F, Helbig U, Weissinger F, Schnoy E, Becker K, Stocker G, Ruschoff J, Eisenmenger A, Karapanagiotou-Schenkel I, Lordick F (2015) Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastrooesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer 51: 569-576.
28. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, Stebbings LA, Leroy C, Jia M, Rance R, Mudie LJ, Gamble SJ, Stephens PJ, Mclaren S, Tarpey PS, Papaemmanuil E, Davies HR, Varela I, Mcbride DJ, Bignell GR, Leung K, Butler AP, Teague JW, Martin S, Jonsson G, Mariani O, Boyault S, Miron P, Fatima A, Langerod A, Aparicio SA, Tutt A, Sieuwerts AM, Borg A, Thomas G, Salomon AV, Richardson AL, Borresen-Dale AL, Futreal PA, Stratton MR, Campbell PJ (2012) The life history of 21 breast cancers. Cell 149: 994-1007.
29. Paterson AL, O'Donovan M, Provenzano E, Murray LJ, Coleman HG, Johnson BT, Mcmanus DT, Novelli M, Lovat LB, Fitzgerald RC (2013a) Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. J Pathol 230: 118-128.
30. Paterson AL, Shannon NB, Lao-Sirieix P, Ong CA, Peters CJ, O'Donovan M, Fitzgerald RC (2013b) A systematic approach to therapeutic target selection in oesophago-gastric cancer. Gut 62: 1415-1424.
31. Sachs N, Clevers H (2014) Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev 24: 68-73.
32. Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A, Bang YJ (2014) Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-A randomized, phase III study. J Clin Oncol 32: 2039-2049.
33. Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP (2013) Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 8: e54014.
34. Shattuck DL, Miller JK, Carraway 3rd KL, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68: 1471-1477.
35. Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, Lopez-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Ruschoff J (2014) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18: 476-484.
36. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, Perou CM, Borresen-Dale AL, Kristensen VN (2010) Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA 107: 16910-16915.
37. Wainberg ZA, Anghel A, DesaiAJ, Ayala R, Luo T, Safran B, FejzoMS, Hecht JR, Slamon DJ, Finn RS (2010) Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 16: 1509-1519.
38. Weaver JMJ, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, Murtaza M, Ong C-AJ, Lao-Sirieix P, Dunning MJ, Smith L, Smith ML, Anderson CL, Carvalho B, O'Donovan M, Underwood TJ, May AP, Grehan N, Hardwick R, Davies J, Oloumi A, Aparicio S, Caldas C, Eldridge MD, Edwards PAW, Rosenfeld N, Tavare S, Fitzgerald RC, The OC (2014) Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 46: 837-843.
39. Zhang Z, Wang J, Ji D, Wang C, Liu R, Wu Z, Liu L, Zhu D, Chang J, Geng R, Xiong L, Fang Q, Li J (2014) Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. Clin Cancer Res 20: 4559-4573.